Working Group Activities

• Charge
• Roster

Translational Medicine and Therapeutics Working Group

The Translational Medicine and Therapeutics (TMAT) Working Group of the SMRB has a two-fold charge of:

1. Identifying the attributes, activities, and functional capabilities of an effective translational medicine program for advancing therapeutics development; and
2. Broadly assessing, from a high-level view, the NIH landscape for extant programs, networks, and centers for inclusion in this program and recommending their optimal organization.

In addressing its charge, the Working Group will consider how the Agency could leverage and organize a wide range of existing NIH resources and effectively implement the Cures Acceleration Network (CAN) (assuming appropriation of funds). Additionally, in executing its charge, the TMAT Working Group should consider the following:

1. Infrastructure, initiatives, and resources with direct relevance to the therapeutic pipeline currently supported by the Agency, including, but not limited to, programs (e.g., TRND Program, Rapid Access to Interventional Development Program, CAN, etc.,) core facilities (e.g., Molecular Libraries Screening Center Network), and clinical research centers (e.g., NIH Clinical Center, CTSAs, etc.,)
2. Methods to synergize with, and avoid competition with, resources in the private sector.
3. Prior recommendations for strengthening the clinical and translational research enterprise at NIH, including recommendations of the IOM in its report Enhancing the Vitality of the National Institutes of Health, and relevant lessons learned from industry, academia, non-profit organizations, etc.;
4. Metrics and methodologies that could be used for evaluating the impact of changes in the organization and management of the therapeutic development program.